Norgine

Norgine company information, Employees & Contact Information

Explore related pages

Related company profiles:

Norgine is a uniquely positioned, specialty pharmaceutical and consumer healthcare company, with more than €500 million of annual revenues and a 120-year track record of bringing life-changing products to patients and consumers across their core markets of Western Europe, Australia, and New Zealand. Today’s Norgine is a nimble, innovative, and high-performing company that has been transformed by a relentless focus on operational excellence to do the right thing by patients, push boundaries, and take strides into new therapeutic areas. The company’s integrated approach – strong commercial capabilities, deep medical, regulatory and clinical expertise, in-house manufacturing, robust supply networks, and best-in-class enabling functions – ensures delivery of high-quality, transformative medicines quickly and effectively to more than 25 million patients annually.

Company Details

Employees
1.06K
Founded
-
Address
Norgine B.v., Antonio Vivaldistraat 150,austria
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Amsterdam, Amsterdam
Looking for a particular Norgine employee's phone or email?

Norgine Questions

News

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma - PR Newswire

Norgine submits Marketing Authorisation Application to the European Medicines Agency for eflornithine (difluoromethylornithine [DFMO]) in high-risk neuroblastoma PR Newswire

Norgine completes acquisition of Theravia - PR Newswire UK

Norgine completes acquisition of Theravia PR Newswire UK

X4 Pharmaceuticals and Norgine Enter into Exclusive - GlobeNewswire

X4 Pharmaceuticals and Norgine Enter into Exclusive GlobeNewswire

EU Approval Is Sought for Eflornithine in High-Risk Neuroblastoma - OncLive

EU Approval Is Sought for Eflornithine in High-Risk Neuroblastoma OncLive

NORGINE B.V. ANNOUNCES NEW EUROPEAN HEALTHCARE SUBSIDIARY - MultiVu

NORGINE B.V. ANNOUNCES NEW EUROPEAN HEALTHCARE SUBSIDIARY MultiVu

Norgine Announces Investment from Goldman Sachs Asset Management - Notimérica

Norgine Announces Investment from Goldman Sachs Asset Management Notimérica

Norgine Announces Closing of Investment from Goldman Sachs Asset Management (2022-12-15) - Seeking Alpha

Norgine Announces Closing of Investment from Goldman Sachs Asset Management (2022-12-15) Seeking Alpha

AMAG Pharmaceuticals and Norgine B.V. Enter Into Exclusive - GlobeNewswire

AMAG Pharmaceuticals and Norgine B.V. Enter Into Exclusive GlobeNewswire

NORGINE B.V. ACQUIRES AZANTA - MultiVu

NORGINE B.V. ACQUIRES AZANTA MultiVu

Norgine B.V. announces Senior Management changes: Christopher Bath appointed Chief Executive Officer - Peter Stein to as - Notimérica

Norgine B.V. announces Senior Management changes: Christopher Bath appointed Chief Executive Officer - Peter Stein to as Notimérica

Norgine Strengthens Senior Leadership with the Appointment of Saulo Martiniano as Chief Operating Officer - PR Newswire

Norgine Strengthens Senior Leadership with the Appointment of Saulo Martiniano as Chief Operating Officer PR Newswire

Norgine B.V. Senior Management Changes: Christopher Bath Appointed Chief Operating Officer - PR Newswire

Norgine B.V. Senior Management Changes: Christopher Bath Appointed Chief Operating Officer PR Newswire

Norgine B.V. Enters Into Exclusive Licence and Distribution Agreements for the Commercialisation of PLENVU® in a Number of Countries in Latin America, Southern Africa, Central and Eastern Europe - PR Newswire

Norgine B.V. Enters Into Exclusive Licence and Distribution Agreements for the Commercialisation of PLENVU® in a Number of Countries in Latin America, Southern Africa, Central and Eastern Europe PR Newswire

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand - PR Newswire

Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand PR Newswire

Norgine B.V. and US WorldMeds enter into exclusive licensing agreement to commercialise DFMO (eflornithine) in Europe, Commonwealth of Independent States, Australia and New Zealand - PR Newswire

Norgine B.V. and US WorldMeds enter into exclusive licensing agreement to commercialise DFMO (eflornithine) in Europe, Commonwealth of Independent States, Australia and New Zealand PR Newswire

Olympus Corporation of the Americas Enters Into US And Canada Distribution Agreement With Arc Medical Design Ltd, A Subsidiary Of Norgine For ENDOCUFF VISION® - PR Newswire

Olympus Corporation of the Americas Enters Into US And Canada Distribution Agreement With Arc Medical Design Ltd, A Subsidiary Of Norgine For ENDOCUFF VISION® PR Newswire

New Data Show Oral Ferric Maltol (FERACCRU®) May Be a Cost-effective Alternative to Intravenous (IV) Carboxymaltose With at Least as Great Benefits in the Quality of Life of Patients With Iron Deficiency Anaemia and Inflammatory Bowel Disease - PR Newswire

New Data Show Oral Ferric Maltol (FERACCRU®) May Be a Cost-effective Alternative to Intravenous (IV) Carboxymaltose With at Least as Great Benefits in the Quality of Life of Patients With Iron Deficiency Anaemia and Inflammatory Bowel Disease PR Newswire

Important New Trial With Oral FERACCRU® Shows Comparable Efficacy to IV Iron (Ferric Carboxymaltose), Offering a Real Alternative to Hospital Administration for Many Patients[4] - PR Newswire

Important New Trial With Oral FERACCRU® Shows Comparable Efficacy to IV Iron (Ferric Carboxymaltose), Offering a Real Alternative to Hospital Administration for Many Patients[4] PR Newswire

Norgine - Role of Colonoscopy - MultiVu

Norgine - Role of Colonoscopy MultiVu

Norgine Announces Appointment of New CEO Janneke van der Kamp - PR Newswire UK

Norgine Announces Appointment of New CEO Janneke van der Kamp PR Newswire UK

Surgical.AI Completes $20-Million Investment in caresyntax, raising caresyntax's Total First Round Financing to $31.9 Million - PR Newswire

Surgical.AI Completes $20-Million Investment in caresyntax, raising caresyntax's Total First Round Financing to $31.9 Million PR Newswire

Salix Receives FDA Approval For PLENVU®, Next Generation 1-Liter Bowel Cleansing Preparation For Colonoscopies - PR Newswire

Salix Receives FDA Approval For PLENVU®, Next Generation 1-Liter Bowel Cleansing Preparation For Colonoscopies PR Newswire

Salix Announces U.S. Launch of PLENVU®, the First and Only 1-Liter PEG Bowel Cleansing Preparation for Colonoscopies - PR Newswire

Salix Announces U.S. Launch of PLENVU®, the First and Only 1-Liter PEG Bowel Cleansing Preparation for Colonoscopies PR Newswire

UEG Week exhibition celebrates 50 years of colonoscopy - MultiVu

UEG Week exhibition celebrates 50 years of colonoscopy MultiVu

Norgine B.V. Completes Important Regulatory Milestone For Angusta® (Misoprostol) In Europe For Oral Induction Of Labour - PR Newswire UK

Norgine B.V. Completes Important Regulatory Milestone For Angusta® (Misoprostol) In Europe For Oral Induction Of Labour PR Newswire UK

Salix to Present Clinical Data for XIFAXAN® (RIFAXIMIN) and PLENVU® at the American College of Gastroenterology Annual Meeting - PR Newswire

Salix to Present Clinical Data for XIFAXAN® (RIFAXIMIN) and PLENVU® at the American College of Gastroenterology Annual Meeting PR Newswire

Luxembourg National Health Fund Approves Reimbursement of XIFAXAN® 550 - European Medical Journal

Luxembourg National Health Fund Approves Reimbursement of XIFAXAN® 550 European Medical Journal

Goldman Sachs’ PE arm to acquire majority stake in Amsterdam-based Norgine, reportedly for €1.8B - Silicon Canals

Goldman Sachs’ PE arm to acquire majority stake in Amsterdam-based Norgine, reportedly for €1.8B Silicon Canals

(NER1006), A LOW VOLUME, PEG BASED BOWEL CLEANSING SOLUTION - MultiVu

(NER1006), A LOW VOLUME, PEG BASED BOWEL CLEANSING SOLUTION MultiVu

Norgine UK launches ANGUSTA® (misoprostol) in the UK for oral induction of labour - PR Newswire UK

Norgine UK launches ANGUSTA® (misoprostol) in the UK for oral induction of labour PR Newswire UK

Norgine Launches Ziverel® in Austria, Belgium, Luxembourg and Switzerland - PR Newswire UK

Norgine Launches Ziverel® in Austria, Belgium, Luxembourg and Switzerland PR Newswire UK

Norgine Launches MOVICOL® Ready to Take (Trinkfertig) in Germany - PR Newswire UK

Norgine Launches MOVICOL® Ready to Take (Trinkfertig) in Germany PR Newswire UK

Top Norgine Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant